📣 VC round data is live. Check it out!

i-SENS Valuation Multiples

Discover revenue and EBITDA valuation multiples for i-SENS and similar public comparables like Gooch & Housego, ECARX Group, Aeluma, Stemmer Imaging and more.

i-SENS Overview

About i-SENS

i-SENS Inc is a Korean company which is engaged in the manufacture and sale of biosensors. The product portfolio of the company includes blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others.


Founded

2000

HQ

South Korea

Employees

N/A

Website

i-sens.com

Financials (LTM)

Revenue: $217M
EBITDA: $17M

EV

$439M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

i-SENS Financials

i-SENS reported last 12-month revenue of $217M and EBITDA of $17M.

In the same LTM period, i-SENS generated $89M in gross profit, $17M in EBITDA, and had net loss of ($1M).


i-SENS P&L

In the most recent fiscal year, i-SENS reported revenue of $216M and EBITDA of $17M.

i-SENS is unprofitable as of last fiscal year, with gross margin of 40%, EBITDA margin of 8%, and net margin of (2%).

See analyst estimates for i-SENS
LTMLast FY202320242025202620272028
Revenue$217M$216M$181M$199M$216M
Gross Profit$89M$86M$73M$78M$86M
Gross Margin41%40%40%39%40%
EBITDA$17M$17M$16M$17M$9M
EBITDA Margin8%8%9%8%4%
EBIT Margin2%3%4%1%3%
Net Profit($1M)($3M)$3M($1M)($4M)
Net Margin(1%)(2%)1%(1%)(2%)
Net Debt$86M

Financial data powered by Morningstar, Inc.

i-SENS Stock Performance

i-SENS has current market cap of $387M, and enterprise value of $439M.


i-SENS's stock price is $14.03.

i-SENS has an EPS (earnings per share) of $-0.12.

See more trading valuation data for i-SENS
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$439M$387M-0.4%$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

i-SENS Valuation Multiples

i-SENS trades at 2.0x EV/Revenue multiple, and 26.0x EV/EBITDA.

See NTM and 2027E valuation multiples for i-SENS

i-SENS Financial Valuation Multiples

As of May 10, 2026, i-SENS has market cap of $387M and EV of $439M.

i-SENS has a P/E ratio of (264.6x).

LTMLast FY202320242025202620272028
EV/Revenue2.0x2.0x2.4x2.2x2.0x
EV/EBITDA26.0x26.0x28.3x26.2x46.7x
EV/EBIT90.6x81.3x58.7x241.2x81.3x
EV/Gross Profit4.9x5.1x6.0x5.6x5.1x
P/En/m(112.6x)152.5xn/m(109.8x)
EV/FCF(141.1x)(81.4x)(21.7x)86.9x(76.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified i-SENS Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

i-SENS Margins & Growth Rates

i-SENS grew revenue by 4% and EBITDA by 0% in the last fiscal year.

In the most recent fiscal year, i-SENS reported gross margin of 40%, EBITDA margin of 8%, and net margin of (2%).

See estimated margins and future growth rates for i-SENS

i-SENS Margins

Last FY202420252026202720282029
Gross Margin40%39%40%43%
EBITDA Margin8%8%4%8%
EBIT Margin3%1%3%2%
Net Margin(2%)(1%)(2%)1%
FCF Margin(2%)3%(3%)0%

i-SENS Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%10%8%4%
Gross Profit Growth14%7%10%14%
EBITDA Growth0%8%(44%)80%
EBIT Growth(26%)(76%)197%(26%)
Net Profit Growth(161%)(148%)187%(160%)
FCF Growth(119%)(125%)(213%)(118%)

Data powered by FactSet, Inc. and Morningstar, Inc.

i-SENS Operational KPIs

i-SENS's Rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

i-SENS's Rule of X is 19% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for i-SENS
LTMLast FY202320242025202620272028
Rule of 4016%12%
Bessemer Rule of X28%19%
S&M Expenses to Revenue8%7%8%8%
G&A Expenses to Revenue3%3%3%3%
R&D Expenses to Revenue10%10%10%10%10%
Opex to Revenue37%36%38%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

i-SENS Competitors

i-SENS competitors include Gooch & Housego, ECARX Group, Aeluma, Stemmer Imaging, LEM Holding, Beijing Piesat Informatio, Smart Eye, Seeing Machines, Sensortek and HUHUTECH.

Most i-SENS public comparables operate across Sensors & Monitoring and Industry 4.0.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Gooch & Housego2.0x1.8x13.2x11.6x
ECARX Group0.9x0.8x(39.5x)680.8x
Aeluma86.4x76.5x(2239.2x)(182.4x)
Stemmer Imaging3.7x38.9x
LEM Holding1.5x1.7x12.5x10.6x
Beijing Piesat Informatio8.9x7.9x(3.3x)
Smart Eye6.7x5.3x542.5x29.9x
Seeing Machines5.1x3.9x(63.9x)71.5x

This data is available for Pro users. Sign up to see all i-SENS competitors and their valuation data.

Start Free Trial

i-SENS Funding History

Before going public, i-SENS raised $10M in total equity funding, across 1 round.


i-SENS Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-21Series ADSC Investment; Korea Investment Partners; Mirae Asset Venture Investment$10M

i-SENS M&A Activity

i-SENS has acquired 2 companies to date.

Last acquisition by i-SENS was on May 17th 2023. i-SENS acquired AgaMatrix for $27M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by i-SENS

AgaMatrix
CoaguSense
Description
AgaMatrix is a Salem, New Hampshire-headquartered developer of diabetes management devices. Its WaveSense technology powers blood glucose meters that correct for hematocrit, temperature, and strip variations, achieving high accuracy. The product line includes JAZZ and PRECIO meters, with Zero-Click data management software. Protected by over 160 patents, the FDA-cleared devices are distributed globally through partnerships with retailers and pharma companies.
CoaguSense is a manufacturer of point-of-care PT/INR monitoring systems for anticoagulation management. U.S.-based, its devices deliver lab-accurate results in seconds using fingerstick samples. Distributed to clinics and home users, the systems support warfarin therapy with data connectivity to EHRs.
HQ CountryUnited StatesUnited States
HQ City
San Francisco, CA
Deal Date17 May 20231 Dec 2016
Valuation$27Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all i-SENS acquisitions and their M&A valuation multiples.

Start Free Trial

i-SENS Investment Activity

i-SENS has invested in 1 company to date.

Latest investment by i-SENS was on November 6th 2023. i-SENS invested in Caremedi in their $20M Series B round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by i-SENS

Caremedi
Description
HQ CountrySouth Korea
HQ City
Deal Date6 Nov 2023
RoundSeries B
Raised$20M
InvestorsAJU IB Investment Co; Atinum Investment; Company K Partners; i-SENS Inc; Korea Investment Partners
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all i-SENS investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About i-SENS

When was i-SENS founded?i-SENS was founded in 2000.
Where is i-SENS headquartered?i-SENS is headquartered in South Korea.
Is i-SENS publicly listed?Yes, i-SENS is a public company listed on Korea Exchange.
What is the stock symbol of i-SENS?i-SENS trades under 099190 ticker.
When did i-SENS go public?i-SENS went public in 2013.
Who are competitors of i-SENS?i-SENS main competitors include Gooch & Housego, ECARX Group, Aeluma, Stemmer Imaging, LEM Holding, Beijing Piesat Informatio, Smart Eye, Seeing Machines, Sensortek, HUHUTECH.
What is the current market cap of i-SENS?i-SENS's current market cap is $387M.
What is the current revenue of i-SENS?i-SENS's last 12 months revenue is $217M.
What is the current revenue growth of i-SENS?i-SENS revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of i-SENS?Current revenue multiple of i-SENS is 2.0x.
Is i-SENS profitable?Yes, i-SENS is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of i-SENS?i-SENS's last 12 months EBITDA is $17M.
What is i-SENS's EBITDA margin?i-SENS's last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of i-SENS?Current EBITDA multiple of i-SENS is 26.0x.
What is the current FCF of i-SENS?i-SENS's last 12 months FCF is ($3M).
What is i-SENS's FCF margin?i-SENS's last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of i-SENS?Current FCF multiple of i-SENS is (141.1x).
How many companies i-SENS has acquired to date?As of May 2026, i-SENS has acquired 2 companies.
What was the largest acquisition by i-SENS?$27M acquisition of AgaMatrix on 17th May 2023 was the largest M&A i-SENS has done to date.
What companies i-SENS acquired?i-SENS acquired AgaMatrix and CoaguSense.
In how many companies i-SENS has invested to date?As of May 2026, i-SENS has invested in 1 company.
What was the last i-SENS investment?On 6th November 2023 i-SENS invested in Caremedi, participating in a $20M Series B round, alongside AJU IB Investment Co, Atinum Investment, Company K Partners, i-SENS Inc, and Korea Investment Partners.
In what companies i-SENS invested in?i-SENS invested in Caremedi.

See public comps similar to i-SENS

Lists including i-SENS

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial